Active — Not RecruitingNot Applicable

Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients

Egypt200 participantsStarted 2023-11-22

Plain-language summary

Heart failure with reduced ejection fraction (HFrEF) is a significant cause of morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving renal outcomes in patients with HFrEF. Pharmacogenetics, the study of how genetic variations influence drug response, could elucidate inter-individual variability in treatment outcomes. This study aims to assess the impact of specific genetic variants on renal outcomes in HFrEF patients treated with SGLT2 inhibitors.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults (≥18 years) with HFrEF (LVEF ≤40%). * Initiation of SGLT2 inhibitor therapy. * Stable background HF therapy for at least 4 weeks. * Written informed consent for participation and genetic testing. Exclusion Criteria: * Known hypersensitivity to SGLT2 inhibitors. * History of ketoacidosis or recurrent urinary tract infections. * End-stage renal disease (eGFR \<30 mL/min/1.73 m²). * Life expectancy \<6 months due to non-cardiovascular conditions. * Pregnancy or lactation.

What they're measuring

Reno-protective effect and gene polymorphism

Timeframe: 6 months

Trial details

NCT IDNCT06901609

SponsorAin Shams University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Heart Failure - NYHA II - IV trials